The Novo deal revived the weight-loss story, but after a violent rebound from $14 to $35, investors are paying upfront for growth that still has to show up.
HIMS Is Back From the Dead.
The Novo deal revived the weight-loss story, but after a violent rebound from $14 to $35, investors are paying upfront for growth that still has to show up.